Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' Profit After Tax rose 2027.85% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.6 million, marking a year-over-year increase of 5235.89%. This contributed to the annual value of $163.9 million for FY2024, which is 12950.43% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Profit After Tax is $52.8 million, which was up 2027.85% from $52.1 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Profit After Tax high stood at $56.7 million for Q1 2025, and its period low was -$30.8 million during Q3 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Profit After Tax value was $25.5 million (recorded in 2022), while the average stood at $27.3 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Profit After Tax plummeted by 23523.83% in 2023 and then skyrocketed by 24264.73% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' Profit After Tax (Quarter) stood at $9.3 million in 2021, then soared by 173.62% to $25.5 million in 2022, then soared by 36.8% to $34.8 million in 2023, then soared by 60.53% to $55.9 million in 2024, then dropped by 5.64% to $52.8 million in 2025.
  • Its Profit After Tax was $52.8 million in Q3 2025, compared to $52.1 million in Q2 2025 and $56.7 million in Q1 2025.